Transgenic Group Inc. (2342.T)
Tokyo · JPY · Healthcare · Biotechnology
¥211 (-3.21%) as of
Key statistics
- Market cap
- 3.51B
- P/E (TTM)
- 104.98
- EPS (TTM)
- 2.01
- Dividend yield
- 0.00%
- 52-week range
- 182.00 – 487.00
- Beta
- 0.47
- Revenue (TTM)
- 13.64B
- Profit margin
- 0.24%
- Volume
- 30.20k
About Transgenic Group Inc.
Transgenic Group Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment and Consulting Business segments. The company provides analysis of the function of individual genes in individuals, elucidation of the relationship between genes and pathology, production of disease model mice, gene expression analysis, and antibody production; clinical trials for pharmaceutical agents, such as bioequivalence studies; administrative services for clinical trials; clinical trials for foods for specified health uses; and hospital support. It also conducts non-clinical studies for pharmaceuticals, medical devices, chemical substances, and food development using small and large animals. In addition, the company offers services related to mergers and acquisitions, business revitalization, business succession, and investment business. The company was formerly known as Trans Genic Inc. and changed its name to Transgenic Group Inc. in October 2024. Transgenic Group Inc. was incorporated in 1998 and is headquartered in Fukuoka City, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Fukuoka City, Japan
- Employees
- 227
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.